Relationship between symptoms, subjective well-being and medication use in gastro-oesophageal reflux disease

International Journal of Clinical Practice

Volumn 61, Issue 8, 2007, Pages 1301-1307

  Jones, R ^a   Liker, H R ^b   Ducrotte P ^c  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c ROUEN UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; HISTAMINE H2 RECEPTOR ANTAGONIST; NON PRESCRIPTION DRUG; PROTON PUMP INHIBITOR;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; BLOATING; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DISEASE SEVERITY; DRUG USE; EATING HABIT; FEAR; FEMALE; FLATULENCE; GASTROESOPHAGEAL REFLUX; HEALTH SURVEY; HEARTBURN; HUMAN; INDIGESTION; LEISURE; MAJOR CLINICAL STUDY; MALE; OBESITY; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; PRODUCTIVITY; SLEEP DISORDER; SMOKING; SYMPTOMATOLOGY; TASTE; TREATMENT RESPONSE; WELLBEING;

ADOLESCENT; ADULT; ANTACIDS; EUROPE; FEMALE; GASTROESOPHAGEAL REFLUX; HEALTH SURVEYS; HUMANS; LIFE STYLE; MALE; MIDDLE AGED; PROTON PUMPS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; UNITED STATES;

EID: 34447343761     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2007.01475.x     Document Type: Article

References (12)

1. Vakil N, Veldhuyzen van Zanten S, Kahrilas P et al. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol 2006 101 : 1900 20.
2. Wiklund I. Review of the quality of life and burden of illness in gastroesophageal reflux disease. Dig Dis 2004 22 : 108 14.
3. Wiklund I, Carlsson J, Vakil N. Gastroesophageal reflux symptoms and well-being in a random sample of the general population of a Swedish community. Am J Gastroenterol 2006 101 : 18 28.
4. Miner P Jr., Katz PO, Chen Y, Sostek M. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. Am J Gastroenterol 2003 98 : 2616 20.
5. Röhss K, Lind T, Wilder-Smith C. Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms. Eur J Clin Pharmacol 2004 60 : 531 9.
6. DeVault KR, Castell DO. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 2005 100 : 190 200.
7. Jones R, Armstrong D, Malfertheiner P et al. Does the treatment of gastroesophageal reflux disease (GERD) meet patients' needs? A survey-based study. Curr Med Res Opin 2006 22 : 657 62.
8. Fass R, Shapiro M, Dekel R et al. Systematic review: proton-pump inhibitor failure in gastro-oesophageal reflux disease - where next? Aliment Pharmacol Ther 2005 22 : 79 94.
9. Dent J, El-Serag HB, Wallander MA et al. Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut 2005 54 : 710 7.
10. Sifrim D, Castell D, Dent J, Kahrilas J. Gastro-oesophageal reflux monitoring: review and consensus report on detection and definitions of acid, non-acid, and gas reflux. Gut 2004 53 : 1024 31.
11. Dean BB, Crawley JA, Schmitt CM et al. The burden of illness of gastro-oesophageal reflux disease: impact on work productivity. Aliment Pharmacol Ther 2003 17 : 1309 17.
12. Kaltenbach T, Crockett S, Gerson LB. Are lifestyle measures effective in patients with gastroesophageal reflux disease? An evidence-based approach. Arch Intern Med 2006 166 : 965 71.